首页>
外国专利>
MC4R AGONIST EFFICACY IN SUBJECTS WITH MC4R DEFICIENCIES AND IMPAIRED NFAT SIGNALING
MC4R AGONIST EFFICACY IN SUBJECTS WITH MC4R DEFICIENCIES AND IMPAIRED NFAT SIGNALING
展开▼
机译:MC4R缺陷和NFAT信号受损的受试者的MC4R促效药
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to a Melanocortin-4 receptor (MC4R) agonist that exhibits greater induction of NFAT signaling compared to a-MSH for use in the treatment and/or prevention of a medical condition associated with MC4R deficiency in a subject having an MC4R deficiency associated with impaired Nuclear factor of activated T-cells (NFAT) signaling. The present invention further relates to an in vitro method for the diagnosis, prognosis and/or assessment of likelihood of whether a subject with, or at risk of having and/or developing, a medical condition associated with MC4R deficiency, will respond to treatment with an MC4R agonist that exhibits greater induction of NFAT signaling compared to a-MSH, the method comprising (i) providing a sample from said subject, and (ii) determining whether the subject has an MC4R deficiency associated with impaired NFAT signaling by assessing said sample, (iii) wherein the presence of an MC4R deficiency associated with impaired NFAT signaling is indicative that treatment with an MC4R agonist that exhibits greater induction of NFAT signaling compared to a-MSH will be effective in said subject.
展开▼